MA28885B1 - vaccins - Google Patents

vaccins

Info

Publication number
MA28885B1
MA28885B1 MA29790A MA29790A MA28885B1 MA 28885 B1 MA28885 B1 MA 28885B1 MA 29790 A MA29790 A MA 29790A MA 29790 A MA29790 A MA 29790A MA 28885 B1 MA28885 B1 MA 28885B1
Authority
MA
Morocco
Prior art keywords
vaccines
Prior art date
Application number
MA29790A
Other languages
English (en)
Inventor
Joseph D Cohen
Nadia Gabriela Tornieporth
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33306702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28885(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA28885B1 publication Critical patent/MA28885B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA29790A 2004-09-16 2007-03-30 vaccins MA28885B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0420634A GB0420634D0 (en) 2004-09-16 2004-09-16 Vaccines

Publications (1)

Publication Number Publication Date
MA28885B1 true MA28885B1 (fr) 2007-09-03

Family

ID=33306702

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29790A MA28885B1 (fr) 2004-09-16 2007-03-30 vaccins

Country Status (18)

Country Link
US (1) US20080102091A1 (fr)
EP (1) EP1791558A2 (fr)
JP (2) JP5670611B2 (fr)
KR (1) KR101362097B1 (fr)
CN (2) CN101056653A (fr)
AR (1) AR051023A1 (fr)
AU (1) AU2005284223B2 (fr)
BR (1) BRPI0515334A (fr)
CA (1) CA2579527C (fr)
GB (1) GB0420634D0 (fr)
IL (1) IL181733A0 (fr)
MA (1) MA28885B1 (fr)
MX (1) MX2007003160A (fr)
NO (1) NO20071523L (fr)
RU (1) RU2423994C2 (fr)
SG (2) SG159520A1 (fr)
TW (1) TW200621287A (fr)
WO (1) WO2006029887A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2794647B2 (ja) 1992-04-17 1998-09-10 株式会社間組 ダム構造とダムの築造法
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
ES2437082T3 (es) 2006-07-18 2014-01-08 Glaxosmithkline Biologicals S.A. Vacunas contra la malaria
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
HRP20161606T1 (hr) * 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
TR201802221T4 (tr) * 2007-08-13 2018-03-21 Glaxosmithkline Biologicals Sa Aşılar.
WO2010108177A2 (fr) * 2009-03-20 2010-09-23 University Of South Florida Procédé et composition utilisant une protéine tyrosine phosphatase à double spécificité en tant que cible de médicament antipaludéen
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
UY35418A (es) * 2013-03-15 2014-10-31 Glaxosmithkline Biolog Sa Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
GB201416773D0 (en) * 2014-09-23 2014-11-05 Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford Novel Methods For Including An Imune Response
WO2016184784A1 (fr) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides comprenant le domaine de liaison des protéines de plasmodium falciparum (cbp1 et cbp2) à cx3cl1 de chimiokine
WO2017048689A1 (fr) * 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Compositions antimalariques et procédés
CN113631573B (zh) 2019-03-25 2024-06-04 国家医疗保健研究所 抗Tau抗体及其在制备用于治疗疾病的药物中的用途
WO2020221451A1 (fr) * 2019-04-30 2020-11-05 Humabs Biomed Sa Anticorps se liant à la protéine circumsporozoïte de plasmodium et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177755T1 (de) 1991-11-16 1999-04-15 Smithkline Beecham Biolog Hybrides protein zwischen cs aus plasmodium und hbsag
DK0671948T3 (da) * 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1201250A1 (fr) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
AU2002306896B2 (en) * 2001-03-26 2007-04-26 Walter Reed Army Institute Of Research Plasmodium falciparum AMA-1 protein and uses thereof
WO2004044167A2 (fr) * 2002-11-12 2004-05-27 Walter Reed Army Institute Of Research Expression, purification et utilisation d'un polypeptide d'antigene lsa-1 de plasmodium falciparum
EP1692285B1 (fr) * 2003-08-15 2012-04-11 Commonwealth Scientific and Industrial Research Organisation Procedes et moyens d'alteration des caracteristiques des fibres dans des plantes produisant des fibres

Also Published As

Publication number Publication date
RU2007109608A (ru) 2008-10-27
AU2005284223A1 (en) 2006-03-23
BRPI0515334A (pt) 2008-07-22
US20080102091A1 (en) 2008-05-01
KR101362097B1 (ko) 2014-02-21
AU2005284223B2 (en) 2011-12-15
AR051023A1 (es) 2006-12-13
WO2006029887A2 (fr) 2006-03-23
EP1791558A2 (fr) 2007-06-06
KR20070052342A (ko) 2007-05-21
JP5632404B2 (ja) 2014-11-26
CN101056653A (zh) 2007-10-17
JP2012116849A (ja) 2012-06-21
NO20071523L (no) 2007-03-28
IL181733A0 (en) 2007-07-04
CA2579527C (fr) 2016-06-21
JP5670611B2 (ja) 2015-02-18
JP2008513400A (ja) 2008-05-01
CN104027795A (zh) 2014-09-10
SG193159A1 (en) 2013-09-30
SG159520A1 (en) 2010-03-30
WO2006029887A3 (fr) 2006-05-11
RU2423994C2 (ru) 2011-07-20
CA2579527A1 (fr) 2006-03-23
TW200621287A (en) 2006-07-01
GB0420634D0 (en) 2004-10-20
MX2007003160A (es) 2007-10-23

Similar Documents

Publication Publication Date Title
MA28609B1 (fr) Vaccins
HUS2200002I1 (hu) Immunogén készítmény
MA28885B1 (fr) vaccins
DK1959991T3 (da) Terapeutisk vaccine
DK1968631T3 (da) Vaccine
TWI365191B (en) Vaccine
ATE462445T1 (de) Prrs-impfstoffe
GB0922611D0 (en) Improved vaccines
MA28639B1 (fr) Vaccins
EP1678292A4 (fr) Vaccins mva ameliores
EP1732597A4 (fr) Vaccin contre streptococcus agalactiae
EP1660636A4 (fr) Vaccins anticancer
EP2061502A4 (fr) Vaccin
GB0411150D0 (en) Vaccine
EP1807116A4 (fr) Vaccination antigrippale
EP1872794A4 (fr) Vaccin nasal
IS8325A (is) Bóluefni
GB0413510D0 (en) Vaccine
EP1948782A4 (fr) Adjuvants de vaccins
GB0412407D0 (en) Vaccine
GB0428381D0 (en) Vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine
AP2709A (en) An anti-theileriosis vaccine
GB0412547D0 (en) Vaccine